Table 3.
Association of N1-MN + 2Py excretion with risk of infectious mortality and noninfectious mortality in KTR 1.
| Model |
N1-MN + 2Py Excretion (log2) As Continuous Variable n = 660 |
|
|---|---|---|
| HR (95% CI) | p-Value | |
| Infectious Mortality | ||
| 1 2 | 0.42 (0.27–0.66) | <0.001 |
| 2 3 | 0.47 (0.29–0.75) | 0.002 |
| 3 4 | 0.47 (0.29–0.75) | 0.002 |
| 4 5 | 0.51 (0.31–0.86) | 0.01 |
| 5 6 | 0.54 (0.34–0.86) | 0.009 |
| 6 7 | 0.54 (0.33–0.88) | 0.01 |
| 7 8 | 0.54 (0.32–0.91) | 0.02 |
| Events (n) | 40 | |
| Noninfectious Mortality | ||
| 1 2 | 0.62 (0.46–0.83) | 0.001 |
| 2 3 | 0.68 (0.50–0.93) | 0.02 |
| 3 4 | 0.67 (0.49–0.92) | 0.01 |
| 4 5 | 0.72 (0.51–1.00) | 0.05 |
| 5 6 | 0.74 (0.54–1.01) | 0.06 |
| 6 7 | 0.75 (0.55–1.03) | 0.08 |
| 7 8 | 0.79 (0.55–1.12) | 0.18 |
| Events (n) | 103 | |
1 The association of N1-MN + 2Py excretion with risk of infectious mortality and noninfectious mortality in KTR was investigated with Cox regression analyses, with adjustment for potential confounders. 2 Model 1: adjusted for sex. 3 Model 2: adjusted as for model 1 and for age and body surface area. 4 Model 3: adjusted as for model 2 and for serum hs-CRP. 5 Model 4: adjusted as for model 2 and for plasma vitamin B6. 6 Model 5: adjusted as for model 2 and for eGFR, proteinuria, and primary renal disease. 7 Model 6: adjusted as for model 2 and for use of proliferation inhibitors, acetylsalicylic acid, and proton pump inhibitors. 8 Model 7: adjusted as for model 2 and for intake of alcohol and energy. CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; N1-MN, N1-methylnicotinamide; KTR, kidney transplant recipients; 2Py, N1-methyl-2-pyridone-5-carboxamide.